Lead sponsor
Altimmune, Inc.
9 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
9
Trials led
2
Active
1,157
Total enrollment
135
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
5
Phase 2
4
Trials by status
Recruiting
1
Active, not recruiting
1
Completed
7
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)BMI ≥25Ph 2Recruiting100
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightBMI ≥25Ph 2Active, not recruiting100
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityBMI 25-40Ph 1Completed100
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)—Ph 1Completed95